Oncternal Therapeutics (NASDAQ:ONCT) Earns Hold Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a research note published on Wednesday. The firm issued a hold rating on the stock.

Several other equities analysts also recently weighed in on ONCT. Brookline Capital Management reaffirmed a “hold” rating on shares of Oncternal Therapeutics in a research note on Thursday, September 12th. Northland Capmk cut Oncternal Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, September 12th. HC Wainwright cut their target price on shares of Oncternal Therapeutics from $19.00 to $18.00 and set a “buy” rating for the company in a research note on Monday, August 12th. Finally, Northland Securities reissued a “market perform” rating and issued a $2.00 price objective on shares of Oncternal Therapeutics in a research report on Thursday, September 12th. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $20.00.

Oncternal Therapeutics Price Performance

Shares of ONCT stock opened at $0.69 on Wednesday. Oncternal Therapeutics has a 1-year low of $0.62 and a 1-year high of $13.14. The firm has a market capitalization of $2.04 million, a PE ratio of -0.06 and a beta of 1.33. The business’s fifty day moving average price is $1.29 and its 200 day moving average price is $4.60.

Institutional Investors Weigh In On Oncternal Therapeutics

A hedge fund recently bought a new stake in Oncternal Therapeutics stock. Pasadena Private Wealth LLC bought a new position in Oncternal Therapeutics, Inc. (NASDAQ:ONCT) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 25,000 shares of the company’s stock, valued at approximately $190,000. Pasadena Private Wealth LLC owned 0.84% of Oncternal Therapeutics at the end of the most recent reporting period. Institutional investors own 16.05% of the company’s stock.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.